Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
+$0.16 today
- Market cap
- $2.16B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
Volume 0.68M
Average 0.94M
CLDX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Celldex Therapeutics, Inc.NASDAQ: CLDX
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $1.16M rose 41.0% year over year, ahead of the +10.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 28.8% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.
Context
- Depreciation & amortization amounted to 225.3% of revenue in FY2025, up 180.1 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +41.0% holds above the trailing-twelve-month pace of +10.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.38M USD
- Year-over-year change
- +6.4%
- 4-year CAGR
- +2.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.38M | +6.4% |
| FY2024 | 2024-12-31 | 3.18M | +5.6% |
| FY2023 | 2023-12-31 | 3.01M | +3.9% |
| FY2022 | 2022-12-31 | 2.9M | -5.6% |
| FY2021 | 2021-12-31 | 3.07M | — |
Depreciation & Amortization vs competitors
How CLDX compares with its peers on the latest reported figures
- CLDX's LTM Sep 2026 depreciation & amortization of $3.73M is the 7th largest of the 10 companies compared; the peer median is $6.94M.
- Its year-over-year change of +10.4% is the 2nd highest of 8, against a peer median of -10.7%.
- Depreciation & amortization amounts to 3333.9% of revenue for CLDX, versus a peer median of 6.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $15.87M | -14.3% | +20.4% | 2.3% | |
| LTM Jun 2026 | $10.17M | -10.7% | +6.1% | 9.7% | |
| LTM Jun 2026 | $10M | +0.0% | +18.6% | 8.5% | |
| LTM Mar 2026 | $7.38M | -44.0% | +24.3% | 6.0% | |
| LTM Mar 2026 | $6.94M | -7.1% | -22.5% | 4.4% | |
| LTM Sep 2026 | $3.76M | +35.4% | +67.3% | — | |
| LTM Sep 2026 | $3.73M | +10.4% | +5.3% | 3333.9% | |
| LTM Jun 2024 | $515.94K | — | -25.9% | 63.2% | |
| LTM Mar 2026 | $468K | -128.3% | — | — | |
| LTM Dec 2025 | $0 | — | -0.5% | 0.0% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CLDX) | $6.94M | -10.7% | +12.3% | 6.0% | |
Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.51M) | (112.33M) | (141.43M) | (157.86M) | (258.76M) |
| Depreciation & Amortization | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M |
| Deferred Income Tax | (227K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.95M | 0 | 23.89M | 34.24M | 36.22M |
| Change in Working Capital | (1.05M) | (3.9M) | 13.46M | (21.6M) | 14.06M |
| Accounts Receivables | 1.57M | (175K) | (2.28M) | 1.93M | (1.32M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.65M | 3.12M | 9.38M | 11.63M | 11.03M |
| Other Working Capital | (6.28M) | (6.85M) | 6.36M | (35.16M) | 4.34M |
| Other Non-Cash Items | (1.14M) | 9.6M | (6.22M) | (15.73M) | (5.84M) |
| Operating Cash Flow | (60.91M) | (103.73M) | (107.29M) | (157.78M) | (210.95M) |
| Capital Expenditures | (1.25M) | (1.83M) | (1.82M) | (1.92M) | (2.71M) |
| Acquisitions (Net) | 27K | 69K | 0 | 0 | 0 |
| Purchases of Investments | (389.88M) | (188.97M) | (424.56M) | (789.92M) | (384.5M) |
| Sales of Investments | 174.95M | 280.67M | 320.6M | 501.71M | 596.29M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (216.16M) | 89.94M | (105.78M) | (290.13M) | 209.07M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 269.89M | 4.08M | 216.22M | 432.3M | 2.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.48M | 0 | 2.24M | 9.15M | 0 |
| Financing Cash Flow | 272.37M | 4.08M | 218.46M | 441.45M | 2.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.69M) | (9.71M) | 5.39M | (6.46M) | 515K |
| Free Cash Flow | (62.16M) | (105.56M) | (109.11M) | (159.7M) | (213.66M) |
Celldex Therapeutics, Inc.
NASDAQ:CLDX
Intrinsic Alpha fair value
Locked
Current Price
$27.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.